A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Summary

The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.

Timeline

Start

2022-05-16

Primary completion

2025-06-04

Completion

2025-06-04

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

Indications